Barclays analyst Matt Miksic reinstated coverage of Medtronic (MDT) with an Overweight rating and $116 price target ahead of the fiscal Q3 report on February 17. The firm expects the company to report strong earnings growth.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT: